Rapid Induction of IL-10 without Affecting IL-12-Induced Systemic Toxicity through a Coexpression of IL-18 Strongly Attenuates

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• IL‐12 immunotherapy of murine leukaemia: comparison of systemic versus gene modified cell therapy

  2009cited by this paper
• Alum with Interleukin-12 Augments Immunity to a Melanoma Peptide Vaccine: Correlation with Time to Relapse in Patients with Resected High-Risk Disease

  2007cited by this paper
• Tumor-specific T cells signal tumor destruction via the lymphotoxin β receptor

  2007cited by this paper
• Controlled-release particulate cytokine adjuvants for cancer therapy.

  2007cited by this paper
• TH1 cells control themselves by producing interleukin-10

  2007cited by this paper
• Conventional T-bet+Foxp3− Th1 cells are the major source of host-protective regulatory IL-10 during intracellular protozoan infection

  2007cited by this paper
• Treatment of AIDS-related Kaposi's sarcoma with interleukin-12: rationale and preliminary evidence of clinical activity.

  2007cited by this paper
• Sepsis: emerging role of nitric oxide and selectins.

  2006cited by this paper
• Multiple interleukin‐18 injections promote both mouse Th1 and Th2 responses after sublethal Escherichia coli infection

  2006influential reference
• Lethal endotoxic shock using alpha-galactosylceramide sensitization as a new experimental model of septic shock.

  2006cited by this paper
• A DNA Vaccine Coding for the Brucella Outer Membrane Protein 31 Confers Protection against B. melitensis and B. ovis Infection by Eliciting a Specific Cytotoxic Response

  2005cited by this paper
• Rapid Conversion of Effector Mechanisms from NK to T Cells during Virus-Induced Lysis of Allogeneic Implants In Vivo1

  2005cited by this paper
• Activated cytotoxic T cells and NK cells in severe sepsis and septic shock and their role in multiple organ dysfunction.

  2005cited by this paper
• Synergistic Effect of IL-2, IL-12, and IL-18 on Thymocyte Apoptosis and Th1/Th2 Cytokine Expression12

  2005cited by this paper
• Phase II Clinical Trial of Interleukin-12 in Patients with Relapsed and Refractory Non-Hodgkin’s Lymphoma and Hodgkin’s Disease

  2004cited by this paper
• Immunological Consequences of Interleukin 12 Administration after Autologous Stem Cell Transplantation

  2004cited by this paper
• Gene therapy of cancer with interleukin-12.

  2003cited by this paper
• IL-12: a promising adjuvant for cancer vaccination

  2003cited by this paper
• Interleukin-12 and the regulation of innate resistance and adaptive immunity

  2003cited by this paper
• Repeated administrations of interleukin (IL)-12 are associated with persistently elevated plasma levels of IL-10 and declining IFN-γ, tumor necrosis factor-α, IL-6, and IL-8 responses

  2003cited by this paper
• Interleukin 12 immunotherapy after autologous stem cell transplantation for hematological malignancies.

  2002cited by this paper
• Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma.

  2002cited by this paper
• Systemic Administration of Naked DNA Encoding Interleukin 12 for the Treatment of Human Papillomavirus DNA-Positive Tumor

  2002cited by this paper
• Phase I Study of Interleukin-12 in combination with Rituximab in patients with B-cell non-Hodgkin lymphoma

  2001cited by this paper
• The Role for Interleukin‐12 Therapy of Cutaneous T Cell Lymphoma

  2001cited by this paper
• Systemic production of IL‐12 by naked DNA mediated gene transfer: toxicity and attenuation of transgene expression in vivo

  2001cited by this paper
• Interleukin-18 regulates both Th1 and Th2 responses.

  2001cited by this paper
• Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12.

  2001cited by this paper
• Genetic heterogeneity in the toxicity to systemic adenoviral gene transfer of interleukin-12

  2001cited by this paper
• IFN-γ-Dependent and -Independent Mechanisms in Adverse Effects Caused by Concomitant Administration of IL-18 and IL-12

  2000influential reference
• Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response.

  2000cited by this paper
• Coadministration of interleukin-18 and interleukin-12 induces a fatal inflammatory response in mice: critical role of natural killer cell interferon-gamma production and STAT-mediated signal transduction.

  2000influential reference
• Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA

  1999cited by this paper
• IL-18 is a potent coinducer of IL-13 in NK and T cells: a new potential role for IL-18 in modulating the immune response.

  1999cited by this paper
• Structure/function relationship of activating Ly-49D and inhibitory Ly-49G2 NK receptors.

  1999cited by this paper
• Gene gun-mediated IL-12 gene therapy induces antitumor effects in the absence of toxicity: a direct comparison with systemic IL-12 protein therapy.

  1999cited by this paper
• Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively.

  1999cited by this paper
• Alleviation of lipopolysaccharide-induced acute liver injury in Propionibacterium acnes-primed IFN-gamma-deficient mice by a concomitant reduction of TNF-alpha, IL-12, and IL-18 production.

  1999cited by this paper
• Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer.

  1999cited by this paper
• Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer.

  1999cited by this paper
• A fatal cytokine-induced systemic inflammatory response reveals a critical role for NK cells.

  1999cited by this paper
• Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response.

  1999cited by this paper
• IFN-gamma-inducing factor/IL-18 administration mediates IFN-gamma- and IL-12-independent antitumor effects.

  1998cited by this paper
• The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses.

  1998cited by this paper
• Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis.

  1998influential reference
• Interleukin 12: A cytokine at the interface of inflammation and immunity

  1998cited by this paper
• Regulation of local host-mediated anti-tumor mechanisms by cytokines: direct and indirect effects on leukocyte recruitment and angiogenesis.

  1997cited by this paper
• Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.

  1997cited by this paper
• Antitumor activities of IL-12 and mechanisms of action.

  1997cited by this paper
• Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10.

  1996cited by this paper
• Interleukin-12 primes human CD4 and CD8 T cell clones for high production of both interferon-gamma and interleukin-10

  1996influential reference
• IL-12-induced IL-10 production by human T cells as a negative feedback for IL-12-induced immune responses.

  1996influential reference
• Role of interferon-gamma in interleukin 12-induced pathology in mice.

  1995cited by this paper

• No citing papers are available for this paper.